CompletedNCT01714713
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study evaluated the safety of EVP-6124 for people with schizophrenia.
Medication studyAges 18–50Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety of EVP-6124 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 127 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 830
- Sponsor
- FORUM Pharmaceuticals Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Canada, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01714713
- Official title
Show the full official title
A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · Anaheim, United States · Bellflower, United States
124 more locations
- Cerritos, United States
- Chino, United States
- Costa Mesa, United States
- Culver City, United States
- Downey, United States
- Escondido, United States
- Garden Grove, United States
- Glendale, United States
- Los Angeles, United States
- Mesa, United States
- Norwalk, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- Riverside, United States
- San Diego, United States
- San Gabriel, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Torrance, United States
- Washington D.C., United States
- Lauderhill, United States
- Miami, United States
- Miami Springs, United States
- North Miami, United States
- Oakland Park, United States
- Orange City, United States
- Orlando, United States
- Atlanta, United States
- Marietta, United States
- Smyrna, United States
- Chicago, United States
- Oak Brook, United States
- Oak Park, United States
- Wichita, United States
- Lake Charles, United States
- Shreveport, United States
- Boston, United States
- Minneapolis, United States
- Flowood, United States
- Creve Coeur, United States
- O'Fallon, United States
- Saint Charles, United States
- St Louis, United States
- Lincoln, United States
- Omaha, United States
- Nashua, United States
- Princeton, United States
- Albuquerque, United States
- Cedarhurst, United States
- Jamaica, United States
- New York, United States
- Charlotte, United States
- Cleveland, United States
- Shaker Hts., United States
- Oklahoma City, United States
- Conshohocken, United States
- Jenkintown, United States
- Norristown, United States
- Philadelphia, United States
- Phoenixville, United States
- Austin, United States
- Dallas, United States
- Salt Lake City, United States
- Bellevue, United States
- Spokane, United States
- La Plata, Argentina
- Mendoza, Argentina
- C.a.b.a, Argentina
- Adelaide, Australia
- Melbourne, Australia
- Mechelen, Belgium
- Calgary, Canada
- Penticton, Canada
- Chatham, Canada
- Kingston, Canada
- Montreal, Canada
- Medellín, Colombia
- Barranquilla, Colombia
- Pereira, Colombia
- Bogota D.C., Colombia
- Berlin, Germany
- Düsseldorf, Germany
- Leipzig, Germany
- Mittweida, Germany
- Stralsund, Germany
- Catania, Italy
- Milan, Italy
- Roma, Italy
- Guadalajara, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Bełchatów, Poland
- Campulung Muscel, Romania
- Oradea, Romania
- Cluj-Napacu, Romania
- Cluj-Napoca, Romania
- Palazu Mare, Romania
- Târgu Mureş, Romania
- Bucharest, Romania
- Talagi, Russia
- Smolensk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Stavropol, Russia
- Yaroslavl, Russia
- Singapore, Singapore
- Salamanca, Spain
- Zamora, Spain
- Alcorcón, Spain
- Coslada, Spain
- Madrid, Spain
- Vil. Stepanivka, Ukraine
- Dnipropetrovsk, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Poltara, Ukraine
- Poltava, Ukraine
- Vinnytsia, Ukraine
- London, United Kingdom
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the safety of EVP-6124 for people with schizophrenia.
Who is behind this study?
The study sponsor is FORUM Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including EVP-6124.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia